Phathom Pharmaceuticals, Inc. Total non-current liabilities

Total non-current liabilities of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Total non-current liabilities growth rates and interactive chart.


Highlights and Quick Summary

  • Total non-current liabilities for the quarter ending September 29, 2021 was $97.1 Million (a 126.62% increase compared to previous quarter)
  • Year-over-year quarterly Total non-current liabilities increased by 114.24%
  • Annual Total non-current liabilities for 2020 was $45.3 Million (a 77.88% increase from previous year)
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Total non-current liabilities of Phathom Pharmaceuticals, Inc.

Most recent Total non-current liabilitiesof PHAT including historical data for past 10 years.

Interactive Chart of Total non-current liabilities of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Total non-current liabilities for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $97.09 $42.84 $41.18
2020 $45.32 $46.83 $50.74 $50.64 $45.32
2019 $25.48 $24.67 $25.48

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.